Coronary Artery DiseaseNCT01788592
Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)
An observational study of Coronary Artery Disease, run by Seung-Jung Park at 1 site in South Korea.
Trial summary
The objective of this study is to evaluate effectiveness and safety of drug-eluting stent implantation in the "real world" daily practice. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease
- How many people
- 50,000 participants
- Where
- 1 siteSouth Korea
- Study dates
- Jan 2003to Oct 2030
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: consecutive patients amenable to percutaneous coronary intervention with drug eluting stents
Who may be able to join
- coronary disease amenable to percutaneous coronary intervention (PCI)
- no clinical and lesion limitations
Who cannot join
- patients with a mixture of several drug eluting stents
- terminal illness with life expectancy less than 1 year
- patients with cardiogenic shock
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Asan Medical Center
Seoul
Seung-Jung Park, MD,PhD, 82-2-3010-4812, sjpark@amc.seoul.kr
Jung-Min Ahn, MD, 82-2-3010-5904, drjmahn@gmail.com
About this study
Official title: Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice
The objective of this study is to evaluate effectiveness and safety of drug-eluting stent implantation in the "real world" daily practice.
- Conditions
- Coronary Artery Disease
- Keywords
- coronary artery disease, drug eluting stent
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Drug eluting stent | Patients who receiving drug eluting stents |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major Adverse Cardiac Event
Death from any causes, myocardial infarction or any repeat revascularization
Measured: 1year
Secondary outcomes (8)
all cause Death
Measured: 1year
Myocardial Infarction
Measured: 1year
The composite of Death or myocardial infarction
Measured: 1year
Any repeat revascularization
Measured: 1year
Target vessel revascularization
Measured: 1year
Target lesion revascularization
Measured: 1year
New lesion revascularization
Measured: 1year
Stent thrombosis by Academic Research Consortium criteria
Measured: 1year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2013 (estimated)
- Study startJan 2003
- Primary completionOct 2030 (estimated)
- Study completionOct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50,000 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Seung-Jung Park
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Seung-Jung Park, Asan Medical Center
- Investigators
- Seung-Jung Park, MD, PhD, Principal investigator, Asan Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01788592
- Sponsor's protocol ID
- AMCCV2013-02
- Status last verified
- Dec 2025
- First submitted
- 8 Feb 2013
- Last updated
- 2 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
Publications
Park SJ, Ahn JM, Park GM, Cho YR, Lee JY, Kim WJ, Han S, Kang SJ, Park DW, Lee SW, Kim YH, Lee CW, Mintz GS, Park SW. Trends in the outcomes of percutaneous coronary intervention with the routine incorporation of fractional flow reserve in real practice. Eur Heart J. 2013 Nov;34(43):3353-61. doi: 10.1093/eurheartj/eht404. Epub 2013 Oct 2.
PubMed 24092248
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice
- ClinicalTrials.gov ID
- NCT01788592
- Acronym / sponsor ID
- AMCCV2013-02
- Conditions
- Coronary Artery Disease
- Keywords
- coronary artery disease, drug eluting stent
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50,000 participants (estimated)
- Lead sponsor
- Seung-Jung ParkUniversity, hospital or other
- Study start
- Jan 2003 (actual)
- Primary completion
- Oct 2030 (estimated)
- Study completion
- Oct 2030 (estimated)
- First posted
- 11 Feb 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate effectiveness and safety of drug-eluting stent implantation in the "real world" daily practice.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Drug eluting stent | – | –Patients who receiving drug eluting stents |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- consecutive patients amenable to percutaneous coronary intervention with drug eluting stents
Key inclusion criteria (2 listed)
- coronary disease amenable to percutaneous coronary intervention (PCI)
- no clinical and lesion limitations
Key exclusion criteria (3 listed)
- patients with a mixture of several drug eluting stents
- terminal illness with life expectancy less than 1 year
- patients with cardiogenic shock
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Major Adverse Cardiac Event
Time frame: 1year
Death from any causes, myocardial infarction or any repeat revascularization
8 secondary outcomes
all cause Death
Time frame: 1year
Myocardial Infarction
Time frame: 1year
The composite of Death or myocardial infarction
Time frame: 1year
Any repeat revascularization
Time frame: 1year
Target vessel revascularization
Time frame: 1year
Target lesion revascularization
Time frame: 1year
New lesion revascularization
Time frame: 1year
Stent thrombosis by Academic Research Consortium criteria
Time frame: 1year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2026.
- Derived from this study: PubMed 24092248Park SJ, Ahn JM, Park GM, Cho YR, Lee JY, Kim WJ, Han S, Kang SJ, Park DW, Lee SW, Kim YH, Lee CW, Mintz GS, Park SW. Trends in the outcomes of percutaneous coronary intervention with the routine incorporation of fractional flow reserve in real practice. Eur Heart J. 2013 Nov;34(43):3353-61. doi: 10.1093/eurheartj/eht404. Epub 2013 Oct 2.
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Seung-Jung Park, MD, PhD principal investigator
Asan Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by Seung-Jung Park at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major Adverse Cardiac Event (time frame: 1year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01788592, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2026.